NovoCure Limited
General ticker "NVCR" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $1.5B (TTM average)
NovoCure Limited follows the US Stock Market performance with the rate: 53.1%.
Estimated limits based on current volatility of 2.1%: low 17.49$, high 18.26$
Factors to consider:
- Total employees count: 1605 (+7.9%) as of 2025
- US accounted for 64.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Market acceptance, Market competition, Capital raising, Distribution issues
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.05$, 17.01$]
- 2026-12-31 to 2027-12-31 estimated range: [6.53$, 15.60$]
Financial Metrics affecting the NVCR estimates:
- Negative: with PPE of -10.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.31 <= 0.28
- Positive: Inventory ratio change, % of 0.37 <= 0.79
- Positive: Investing cash flow per share per price, % of 29.51 > -0.64
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 42.26 < Shareholder equity ratio, % of 42.33 <= 63.63
- Negative: negative Net income
- Positive: 0 < Industry operating cash flow per share per price (median), % of 1.58
- Positive: -9.15 < Industry operating profit margin (median), % of -7.42
Short-term NVCR quotes
Long-term NVCR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $509.34MM | $605.22MM | $655.35MM |
| Operating Expenses | $742.21MM | $775.72MM | $809.15MM |
| Operating Income | $-232.87MM | $-170.50MM | $-153.80MM |
| Non-Operating Income | $41.13MM | $39.33MM | $17.55MM |
| R&D Expense | $223.06MM | $209.65MM | $224.54MM |
| Income(Loss) | $-191.74MM | $-131.16MM | $-136.25MM |
| Taxes | $15.30MM | $37.47MM | $-0.02MM |
| Net Income(Loss)* | $-207.04MM | $-168.63MM | $-136.23MM |
| Stockholders Equity | $362.50MM | $360.18MM | $340.47MM |
| Inventory | $38.15MM | $35.09MM | $41.11MM |
| Assets | $1,146.13MM | $1,240.78MM | $804.33MM |
| Operating Cash Flow | $-73.34MM | $-26.37MM | $-49.03MM |
| Capital expenditure | $27.09MM | $42.85MM | $26.65MM |
| Investing Cash Flow | $184.15MM | $-140.24MM | $437.28MM |
| Financing Cash Flow | $15.79MM | $90.31MM | $-451.34MM |
| Earnings Per Share** | $-1.95 | $-1.56 | $-1.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.